Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients

समान संसाधन

• P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
  द्वारा: Frida Bugge Askeland, और अन्य
  प्रकाशित: (2023-08-01)
• P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
  द्वारा: F. B. Askeland, और अन्य
  प्रकाशित: (2022-06-01)
• Comparison of bortezomib-cyclophosphamide-dexamethasone <em>versus</em> bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients
  द्वारा: Rafiye Ciftciler, और अन्य
  प्रकाशित: (2020-05-01)
• Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
  द्वारा: Yan Wang, और अन्य
  प्रकाशित: (2025-02-01)
• Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
  द्वारा: Edvan De Queiroz Crusoe, और अन्य
  प्रकाशित: (2020-04-01)